Doug. Thank you,
out lingering across earlier, the As mentioned Doug globe. due with the year some started challenges COVID to
that second has the first the was QX. rebound quarter nice there a continued of half into However, in
results U.S. Our coronary, team board and strong business. finished across the our solid the international with quarter U.S. peripheral from
continues execute team to at a level. sales U.S. high Our
largely but procedures, Regarding an the was impact broader to environment we contained January. cases certainly to saw especially peripheral it
the after slump. Our U.S. business hospital-based well January recovered peripheral
are with strong IVL by These Further soft space customers followed healthy continuing volumes. their and other tool to critical experience March. seem patients patients. procedural January most ischemia are treat companies a and increasingly Our they as consistent their product reported in calcified return heavily our for choice their February a have dynamics of a monthly and choosing
in highest products. both February for daily and U.S. peripheral had our average fact, we In sales in history the coronary the
record this was in surpassed March. Fortunately,
of purchased peripheral. During coronary, purchased products. accounts only the and purchased coronary peripheral XX% XX% our XX% quarter and both U.S. only
of accounts We increase and continued in products. coronary purchasing see the are both pleased peripheral the proportion our to
use do IVL. use IVL use use to is is who those The peripheral same peripheral IVL. is goal using our our accounts that in in coronary accounts is that that both peripheral customers show of have also peripheral use to compared peripheral It of use data IVL. not all accounts coronary Our and also IVL coronary than only it that in true IVL higher
of customers. IVL During represented with first to the of XX% the continues grow the in existing that use the U.S. reorders revenue indicating CX quarter
We expect available to diminishes. the reorder number this new grow accounts metric of as
volume continue physicians will of be help for target our this been XXX accounts, year. accounts. accounts IVL launched. We of launching are three and focus launched the CX Said have over Meanwhile, of training a customer remaining Throughout ongoing now high the our per un-launched to rest stopped To clear the we our This used these have throughout on using entire which comprised that centers year, will and and differently year. will be yet focus that the quarters group accounts not launched for products. of of they These in in over not education are accounts. target the coronary the to be facilities perform that most have PCIs penetration with staff comfortable IVL. drive their business tailwind will accounts those ensure help and are
growth that supported saw for peripheral went XX% Our quarter-on-quarter increased procedures knee into by IVL reimbursement the on U.S. effect above strong business January outpatient Xst. was peripheral the and of
will use hard is uplifts certainly and reimbursement atherectomy barrier economic is the removes increased the which equivalent quantify payment of our to to clinically the reimbursement, allow appropriate. for While whenever to our customers IVL impact the them it now
MX+ earlier, April. mentioned transitioned Doug launch of a in to As full commercial we
Our is with saw you MX+ CX. launch what strategy to similar with
the to confidence that give We our field. out product roll returned are quarter deliberate very the to to working controlled calcified similar the in the results PAD pre-pandemic Again, hospital levels at us to have customers in period. manner this a treating
our UK side, of the new to international results. record the France excellent bulk growth and Coronary On also delivered the drove international Again, business. represents our IV growth. lead these in we teams
the U.S. However, we different in The U.S. atherectomy continue in to peripheral are driving peripheral mainly increase our international is adoption. the use uncommon. market on dynamics peripheral the IVL focus and outside efforts
spend time modification peripheral new calcium their So those countries. in of our building teams segment a
progress We have symptomatic further peripheral launch building Germany for and SX and for new traditionally our and done our business. serve both Italy, the IVL international France and well as made peripheral MX+ significant more our access. will disease The business, UK catalyst of our a teams in in recently have
Europe, about in marketing also customers have peripheral establishing the programs to our We and more increased efforts IVL for and of benefits mechanism IVL. teach are
feel see to cadaver recently were heavily As calcified with an a surgeons heavily model. peripheral surgeons changes hands. example, the feel of able in with demonstration of were IVL how calcified and a the IVL on the team It's IVL of to change performed remarkable significantly and workshop physicians The impact able demonstrate compliance arteries. impact to these calcified artery the a own the of their the
these customer usage and our expect We over will of time. increase base efforts IVL
in Turning cases we product we of are centers help CX ensure we about plan In receiving key Japan. QX, perform launch. full will on the in to to that a Asia, after the for recent We approval to interim in that excited launch limited-basis reimbursement. the are prepared the
will approach in other use. on as countries method focus We a training the Japan in education and the in on have launch same with done we appropriate
And and of lack already X,XXX Japan than the the accounts. to IVL they've additions countries compendium Spain, financials. emerged being will pandemic. relatively than continues IVL XXX to as Netherlands launch of of a data. In With in that, short-time the smaller be collected they expect We business registries enrolled our to including perform India in the turn registry. data the will the slower very the business more I to along from in Japan size France, data of the significant a team other be call finally, be the those to the in the review because post-market Dan in and patient These in have IVL patients primarily existing will what and well Italy, in U.S. with
